Diffusion-weighted imaging in identifying breast cancer pathological response to neoadjuvant chemotherapy: A meta-analysis

• DOI: 10.18632/oncotarget.23195
• Publication Date: 2017-12-13T17:16:01Z
• Authors: Wei Chu; Weiwei Jin; Daihong Liu; Jian Wang; Chengjun Geng; Lihua Chen; Xuequan Huang
• Keywords: Subgroup analysis

// Wei Chu 1, * , Weiwei Jin 2, Daihong Liu 3 Jian Wang Chengjun Geng 4 Lihua Chen and Xuequan Huang 1 Department of Radiology, Wuxi Huishan District People’s Hospital, Jiangsu Province, 214187, China 2 Second Traditional Chinese Medicine 214121, Southwest Third Military Medical University, Chongqing, 400038, PLA No.101 Wuxi, 214044, These authors contributed equally to this work Correspondence to: Huang, email: [e-mail] Chen, [e-mail] Keywords: magnetic resonance imaging; diffusion-weighted neoadjuvant chemotherapy; breast cancer; meta-analysis Received: October 27, 2017      Accepted: December 01, Published: 11, 2017 ABSTRACT Background: Diffusion-weighted imaging (DWI) is increasingly used identify pathological complete responses (pCRs) chemotherapy (NAC) in cancer. The aim the present study was assess utility DWI using a pooled analysis. Materials Methods: Literature databases were searched prior July 2017. Fifteen studies with total 1181 patients included. data extracted perform analysis, heterogeneity testing, threshold effect sensitivity publication bias analysis subgroup analyses. Result: methodological quality moderate. Remarkable detected, primarily due effect. weighted values 0.88 (95% confidence interval (CI): 0.81, 0.92), specificity 0.79 CI: 0.70, 0.86), positive likelihood ratio 4.1 2.9, 5.9), negative 0.16 0.10, 0.24), diagnostic odds 26 15, 46). area under receiver operator characteristic curve 0.91 0.88, 0.93). In change apparent diffusion coefficient (ADC) higher than that pre-treatment ADC (0.80 [95% 0.71, 087] vs. 0.63 0.52, 0.73], P = 0.027). Conclusions: may be an accurate nonradioactive technique for identifying pCRs NAC Nonetheless, there are variety issues when assessing techniques estimating cancer NAC, large scale well-designed clinical trials needed technique’s value.